Biomarkers and antibodies

Through in-house research and partnership programs with pharmaceutical companies and academic groups, we are continuously expanding our extensive portfolio of state-of-the-art biomarkers and antibodies. These qualified antibodies are exclusively available to our partners and collaborators.

Robust and reliable assays for cerebrospinal fluid (CSF) and blood can be developed with these antibodies to detect neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and traumatic brain injury.

Discover our portfolio below. Request a test-sample to verify the unique performance of our materials or let us know how we can help you.

Get in touch

ADx monoclonal antibodies

Amyloid

Amyloid-beta is a useful biomarker for the detection of the Alzheimer pathology, even in an early stage. Decreased amyloid-beta 42/40 ratio in CSF and plasma correlates highly with the presence of amyloid plaques in Alzheimer brains.

Available antibodies

ADx101Mouse monoclonal antibody against human β Amyloid 1-x1 specific
ADx102Mouse monoclonal antibody against human β Amyloid x-4242 specific
ADx103Mouse monoclonal antibody against human β Amyloid x-4040 specific
ADx104Mouse monoclonal antibody against human β Amyloid x-3838 specific
ADx401Mouse monoclonal antibody against human BACE-1
ADx402Mouse monoclonal antibody against human BACE-1

Literature

Tau

Total tau and P-tau are good indicators of neuronal damage. P-tau specifically measures damage caused by Alzheimer’s disease. In contrast, total tau is a general marker, which can also be used to determine severe concussion.

Available antibodies

ADx201Mouse monoclonal antibody against human total tauMid tau
ADx202Mouse monoclonal antibody against human total tauMid tau
ADx215Mouse monoclonal antibody against human total tauN-terminal tau
ADx203Mouse monoclonal antibody against human total tauMid tau
ADx204Mouse monoclonal antibody against human total tauN-terminal tau
ADx205Mouse monoclonal antibody against human total tauMid tau
ADx252Mouse monoclonal antibody against human P-tau181Phosphorylated Threonine 181 specific
ADx253Mouse monoclonal antibody against human P-tau231Phosphorylated Threonine 231 specific

Literature

Synapses

Neurons are interconnected by multiple synapses. In Alzheimer’s disease, synapses show gradual degeneration. Neurogranin, BACE-1 and Neuronal Pentraxin 2 (NPTX2) in CSF are good biomarkers for synapse integrity. They will help predict the progression of the disease.

Available antibodies

ADx401Mouse monoclonal antibody against human BACE-1
ADx402Mouse monoclonal antibody against human BACE-1
ADx403Mouse monoclonal antibody against human neurograninN-terminal
ADx451Mouse monoclonal antibody against human truncated neurogranin Specific for C-terminal truncation at P75

Literature

Synuclein

The concentration of α-synuclein in CSF is linked to the presence of Lewy bodies in the brain, which are typically found in the brains of Parkinson’s disease patients. Other α-synuclein forms are in development.

Available antibodies

ADx301Rabbit monoclonal antibody against human α-synuclein
ADx302Rabbit monoclonal antibody against human α-synuclein

Literature

Commercial immunoassays

Some of the ADx markers were developed and commercialized in collaboration with our partners. The new generation of Alzheimer’s diagnostics, using Ab 1-40, Ab 1-42, P-tau, total tau, neurogranin and synuclein is now available through our partner Euroimmun, a Perkin Elmer company.

For the development of highly sensitive blood tests, we are collaborating with IVD enterprise Quanterix.

ADx antibodies are adaptable to any technology. We are currently exploring additional partnerships with several diagnostic companies.

Find out more on our partner’s websites or get in touch to request more information.

Get in touch